Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889859 | 0.85 | CHRM2 (0.42) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL4882920 | 0.84 | FUCA1 (0.41) | — | |
| SCHEMBL4880745 | 0.81 | MEN1 (0.38) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL4882984 | 0.79 | CHRM3 (0.40) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL4886880 | 0.77 | CHRM3 (0.51) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL4084970 | 0.74 | CHRM2 (0.72) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4084084 | 0.74 | CHRM2 (0.72) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948227 | 0.73 | CHRM2 (0.71) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948020 | 0.73 | CHRM2 (0.71) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5948399 | 0.72 | CHRM2 (0.69) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | claimed |
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 5/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.